Huntington’s Disease Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2034

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

This report covers the 7MM and provides an Excel-based forecast model for the Huntington’s Disease market through 2034.

The current HD treatments are used to alleviate the symptoms associated with the disease, with all of the approved drugs indicated for the management of chorea associated with HD. VMAT2 inhibitors dominated the HD market in 2024, accounting for 99.8% of sales in the 7MM. The key focus in the pipeline is on developing DMTs for HD, and huntingtin-lowering strategies are key area of development. Companies are pursuing various mechanisms to achieve this, including gene therapies, antisense oligonucleotides (ASOs), and oral therapeutics. The HD market across the 7MM was valued at $0.3 billion in the 2024 baseline year and is projected to grow at a compound annual growth rate (CAGR) of 27.4%, reaching $3.8 billion by 2034. A key driver of growth will be the launch of seven late-stage pipeline products, including the first DMTs for HD.

Scope

Overview of Huntington’s Disease (HD), including epidemiology, symptoms, diagnosis, and disease management.

Annualized HD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2024 to 2034.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the HD market.

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for HD. The most promising candidates in late-stage development are profiled.

Analysis of the current and future market competition in the 7MM HD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

During the 10-year forecast period, there are two major pipeline products on track to launch, driving a forecast growth in the 3MM from $251.7m in 2020 to $917.7m in 2030.

Neurocrine’s Ingrezza (valbenazine) is expected to launch in the US in 2023, and it will directly compete with Teva’s Austedo (deutertabenazine).

Huntexil is expected to launch in 2025 in the US and in 2026 in Germany and the UK. As it will target the non-choreic symptoms, it will likely be prescribed on top of other treatments, or it will replace some off-label drug use.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the 7MM HD therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HD therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents (PowerPoint Deck)

Contents

Abbreviations

Related Reports

Executive Summary

Disease Overview

Overview of HD

Pathophysiology of HD

Staging Systems of HD

Huntington’s Disease Integrated Staging System

HD SWOT Analysis

Epidemiology

Diagnosed Incident Cases of Manifest HD, Both Sexes, All Ages, 2024–34

Age-Specific Trends in Diagnosed Incident Cases of Manifest HD, Both Sexes, 2024

Sex-Specific Diagnosed Incident Cases of Manifest HD, All Ages, 2024

Diagnosed Prevalent Cases of All HD (Premanifest and Manifest Combined), Both Sexes, All Ages, 2024–34

Diagnosed Prevalent Cases of Premanifest HD, Both Sexes, All Ages, 2024–34

Diagnosed Prevalent Cases of Manifest HD, Both Sexes, All Ages, 2024–34

Age-Specific Trends in Diagnosed Prevalent Cases of Manifest HD, Both Sexes, 2024

Sex-Specific Diagnosed Prevalent Cases of Manifest HD, All Ages, 2024

Diagnosed Prevalent Cases of Manifest HD by Type, All Ages, Both Sexes, 2024

Diagnosed Prevalent Cases of Adult-Onset Manifest HD by Stage, All Ages, Both Sexes, 2024

Sources and Methodology for Diagnosed Incident Cases of Manifest HD

Sources and Methodology for Diagnosed Prevalent Cases of All HD

Sources and Methodology for Diagnosed Prevalent Cases of Premanifest HD

Sources and Methodology for Diagnosed Prevalent Cases of Manifest HD

Sources and Methodology for Manifest HD by Type

Sources and Methodology for Adult-Onset Manifest HD by Stage

Sources and Methodology for Diagnosed Incident Cases of Manifest HD

Sources and Methodology for Diagnosed Prevalent Cases of All HD

Sources and Methodology for Diagnosed Prevalent Cases of Premanifest HD

Sources and Methodology for Diagnosed Prevalent Cases of Manifest HD

Current Treatment Options

Treatment Paradigm

Current Treatment Options

Product Profile: Bausch Health’s Xenazine/Nitoman/Choreazine (tetrabenazine)

Product Profile: Teva’s Austedo/Austedo XR (deutetrabenzine/deutetrabenzine ER)

Product Profile: Neurocrine Biosciences’ Ingrezza/Ingrezza Sprinkle (valbenazine)

Product Profile: Sanofi’s Tiaprizal/Tiapridal/Sereprile/Gramalil (tiapride)

Patient Flow: HD in 2024 Across 7MM

Unmet Needs and Opportunities

Unmet Needs in HD

Disease-Modifying Therapies

Early Diagnosis and Consensus on Disease Staging

Treatment Options for Cognitive and Psychiatric Symptoms

R&D Strategies

Trends in Clinical Trial Design in HD

Trends in Deal-Making in HD

Pipeline Assessment

HD Pipeline Overview

Late-Stage Pipeline Agents for HD

Product Profile: SOM Biotech’s SOM-3355 (bevantolol hydrochloride)

Product Profile: Prilenia Therapeutics’ Huntexil (pridopidine)

Product Profile: Roche’s RG6042 (tominersen)

Product Profile: Wave Life Sciences’ WVE-003

Product Profile: uniQure’s AMT-130 (ifezuntirgene inilparvovec)

Product Profile: PTC Therapeutics/Novartis’s PTC518 (votoplam)

Product Profile: Skyhawk Therapeutics’ SKY-0515

HD: Clinical Trials (Phase II/III) Overview

Market Outlook

HD Market Forecast

Market Drivers and Barriers

Appendix

Primary Research: KOL Information

Primary Research: High Prescriber Survey Information

Bibliography

About the Authors

Contact Us

Huntington’s Disease Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2034 standard reports
Currency USD
$17,995

Can be used by individual purchaser only

$53,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Huntington’s Disease Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2034 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Huntington’s Disease Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2034 in real time.

  • Access a live Huntington’s Disease Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2034 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.